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Summary
International asthma management guidelines recommend a long-acting b2-agonist (LABA) as
add-on therapy in patients whose asthma is not controlled by low-dose inhaled corticosteroid
(ICS) monotherapy. Treatment with a single inhaler containing an ICS/LABA combination is
advocated because it may facilitate adherence to a regimen. When prescribing ICS/LABA
combination therapy, the potency of the ICS and the speed of onset of the LABA are
considered important factors; therefore, an inhaled therapy containing components with
these properties may be valued by physicians. The ICS ﬂuticasone propionate (ﬂuticasone)
has potent and sustained anti-inﬂammatory effects, and the LABA formoterol fumarate
(formoterol) provides rapid bronchodilation; the efﬁcacy and safety proﬁles of these agents
have been well established in clinical practice. Fluticasone and formoterol have been
combined, for the ﬁrst time, in a single hydroﬂuoroalkane-based aerosol (ﬂutiform®;
ﬂuticasone propionate/formoterol fumarate). Here, we review data from the published
randomized, controlled, clinical trials that demonstrate the efﬁcacy and tolerability of this
product. It has been shown that ﬂuticasone/formoterol is more efﬁcacious than ﬂuticasone
or formoterol given alone, and provides similar improvements in lung function to ﬂuticasone
and formoterol administered concurrently via separate inhalers. Fluticasone/formoterol
has similar efﬁcacy and tolerability proﬁles to budesonide/formoterol and ﬂuticasone/
salmeterol, but with the additional beneﬁt of more rapid bronchodilation than ﬂuticasone/
salmeterol.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
International asthma management guidelines recommend
that a long-acting b2-agonist (LABA) is prescribed as an
add-on therapy for patients whose asthma is not controlled
by low-dose inhaled corticosteroid (ICS) monotherapy.1
A substantial evidence base shows that co-administration
of a LABA and an ICS results in better clinical effectiveness
than that achieved with an ICS alone.2 4 It has also been
shown that the addition of a LABA to existing low-dose
ICS therapy is more effective at reducing the risk of a
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severe exacerbation or a poorly controlled asthma day
than doubling the dose of ICS administered.5 Combining
an ICS and a LABA in a single inhaler may encourage
improved adherence to the treatment regimen and may be
preferred by patients to the use of separate inhalers.6,7
Until recently, only three ICS/LABA ﬁxed-dose combinations
were available in Europe, and data from randomized,
controlled, clinical trials have demonstrated that each of
these products is highly efﬁcacious.8 13 However, many
patients do not achieve control of their asthma even
when they are prescribed ICS/LABA therapy.14,15 There
are several possible reasons for this: the effectiveness of
any inhaled asthma therapy in everyday clinical practice
is inﬂuenced by drug efﬁcacy and delivery, and requires
the correct inhalation technique, handling of the device
and patient adherence to their treatment regimen.16,17
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Incomplete control of asthma disrupts the lives of patients
and has a large impact on their health and health-
related quality of life.15,18,19 As a consequence, morbidity
associated with uncontrolled asthma remains a signiﬁcant
worldwide health and economic problem.1 The development
of alternative therapies is therefore required, especially for
the treatment of patients whose asthma responds poorly to
current therapies.20 A recent Delphi initiative (sponsored by
Mundipharma International Limited) has shown that a panel
of expert respiratory specialists considered the potency
of the ICS and speed of onset of the LABA among the
factors to be most important when prescribing an ICS/LABA
combination therapy for asthma.21 A rapid onset of action
is also important to patients; data show that patients want
to feel their combination therapy working quickly, while
providing lasting therapeutic beneﬁts.22 24 Importantly,
patients who were non-adherent to a regimen identiﬁed
rapid bronchodilation (‘If I could feel it helping my asthma
soon after taking it’) among the leading factors that would
encourage adherence; indeed, a key reason given for poor
adherence to asthma maintenance therapy is the lack of a
rapid effect.25,26 Taken together, these data might suggest
that the combination of the ICS ﬂuticasone propionate
(ﬂuticasone), which has potent anti-inﬂammatory effects,
and the LABA formoterol fumarate (formoterol), which
provides rapid bronchodilation,27 provides an additional
treatment option for asthma that may be valued by both
physicians (see Price and Bousquet28 in this supplement) and
patients.22 26
The efﬁcacy and safety proﬁle of ﬂuticasone is well
established; it is a widely prescribed,29 highly effective
maintenance treatment for asthma, both as a single-
inhaler therapy30 and as the ICS component of the ﬁxed-
dose combination ﬂuticasone/salmeterol.12,13 Fluticasone
exhibits potent anti-inﬂammatory activity in vitro and
in vivo .31 33 Furthermore, it undergoes a high level
of ﬁrst-pass metabolism and has a signiﬁcantly lower
oral bioavailability than budesonide or beclometasone
dipropionate (<1% versus ~11% and 13 26%, respectively
[26 40% for the active metabolite beclometasone-17-
monopropionate]).34 36 The efﬁcacy and safety proﬁle of
formoterol is also well established.37 Formoterol provides
signiﬁcantly more rapid bronchodilation than salmeterol
comparable to that of the short-acting b2-agonist salbuta-
mol.38 41 Formoterol is the LABA component of the ﬁxed-
dose combinations of budesonide/formoterol and beclo-
metasone/formoterol. Fluticasone and formoterol have
been combined for the ﬁrst time in a single hydro-
ﬂuoroalkane (HFA)-based pressurized metered-dose inhaler
(pMDI; ﬂutiform®). Fluticasone/formoterol is formulated
as a suspension aerosol; other available ICS/LABA aerosol
combinations are prepared in suspension (ﬂuticasone/
salmeterol; also available as a dry-powder inhaler) or
solution (beclometasone/formoterol) formulations. Across
most of Europe, budesonide/formoterol is only available in
a dry-powder inhaler.
Fluticasone/formoterol has been approved in Europe for
the regular treatment of asthma in adults and adolescents
(12 years and above) with symptoms that are uncontrolled
on an ICS alone, or controlled using an ICS in combination
with a LABA.27 This review provides an overview of
the published data from a comprehensive clinical trial
programme that demonstrates the efﬁcacy and tolerability
proﬁles of ﬂuticasone/formoterol.
Efﬁcacy of ﬂuticasone/formoterol versus its
components administered alone
Data from four clinical trials have demonstrated that
ﬂuticasone/formoterol is superior to its components admin-
istered as monotherapies for improvement in measures of
lung function and asthma control.42 45 Two of these studies
have been published and are summarized here.42,43 Both
studies compared ﬂuticasone/formoterol with ﬂuticasone
or formoterol administered as monotherapies, and with
a placebo over a 12-week period, and both were of
double-blind, placebo- and active-controlled, parallel-group
design. These studies assessed the contribution of the
individual components to the efﬁcacy of the ICS/LABA
combination as co-primary endpoints. The contribution of
the ICS component was assessed by comparing ﬂuticasone/
formoterol with formoterol alone for mean change in forced
expiratory volume in 1 second (FEV1) from morning pre-dose
at baseline to pre-dose at week 12. The contribution of the
LABA component was assessed by comparing ﬂuticasone/
formoterol with ﬂuticasone alone for mean change in
FEV1 from morning pre-dose at baseline to 2 hours post-
dose at week 12. The third co-primary endpoint, time
to discontinuation due to lack of efﬁcacy, was used to
evaluate the efﬁcacy of ﬂuticasone/formoterol compared
with placebo. Primary efﬁcacy analyses were carried out
using the full analysis set (all patients who received at least
one dose of treatment and had measurements for pre-dose
baseline FEV1, at least one post-baseline pre-dose FEV1 and
at least one post-baseline post-dose FEV1).
The ﬁrst study assessed the efﬁcacy of low-dose
ﬂuticasone/formoterol in 475 adolescent and adult patients
with asthma (60 85% predicted FEV1 at baseline), who
were randomly assigned to receive ﬂuticasone/formoterol
(100/10mg twice daily [b.i.d.]), ﬂuticasone alone (100mg
b.i.d.), formoterol alone (10mg b.i.d.) or placebo, all
administered via an HFA-based pMDI (EudraCT number:
2007-002866-36; US NCT number: NCT00393991).43
Fluticasone/formoterol was superior to formoterol admin-
istered alone for increase from baseline to week 12 in mean
morning pre-dose FEV1 (least-squares [LS] mean between-
treatment difference: 0.101 L; 95% conﬁdence interval [CI]:
0.002, 0.199; p = 0.045), demonstrating the contribution of
the ﬂuticasone component of the combination treatment.
In addition, ﬂuticasone/formoterol provided signiﬁcantly
greater improvement in mean morning FEV1 than ﬂuticasone
monotherapy from pre-dose at baseline to 2 hours post-dose
at week 12 (LS mean between-treatment difference: 0.200 L
(95%CI: 0.109, 0.292; p < 0.001), which highlighted the
contribution of formoterol to the combination. Fluticasone/
formoterol was associated with a signiﬁcantly longer time to
discontinuation due to lack of efﬁcacy (assessed as either an
asthma exacerbation or a loss of asthma control; p = 0.015),
compared with placebo. Furthermore, fewer patients in
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the ﬂuticasone/formoterol treatment group discontinued
therapy due to lack of efﬁcacy (6.1%) compared with
the ﬂuticasone, formoterol or placebo groups (7.7%, 11.2%
and 16.2%, respectively).43
Fluticasone/formoterol provided a signiﬁcant reduction
in rescue medication use compared with ﬂuticasone alone
(p = 0.008). Fluticasone/formoterol also provided greater
improvement than ﬂuticasone alone in several clinically
meaningful secondary endpoints, such as decrease in
symptom-free days (p = 0.027) and asthma control days
(p = 0.017). Although these endpoints had a p value of
0.05 versus ﬂuticasone alone, they were not considered
statistically signiﬁcant per the sequential gatekeeper
approach used in the study.43
In the second study, which assessed medium-dose
ﬂuticasone/formoterol versus its individual components
administered alone, 557 adolescent and adult patients
with asthma (40 80% predicted FEV1 at baseline) were
randomly assigned to treatment with ﬂuticasone/formoterol
(medium dose, 250/10mg b.i.d. for the co-primary end-
points), ﬂuticasone alone (250mg b.i.d.), formoterol alone
(10mg b.i.d.) or placebo; patients were also assigned
to a ﬂuticasone/formoterol exploratory group (low dose,
100/10mg b.i.d.); all treatments were administered via an
HFA-based pMDI (EudraCT number: 2006-005989-39; US NCT
number: NCT00393952).42
Medium-dose ﬂuticasone/formoterol was superior to
formoterol administered alone for change in mean FEV1
from pre-dose at baseline to pre-dose at week 12
(LS mean between-treatment difference: 0.189 L; 95%CI:
0.079, 0.298; p < 0.001). Similarly, ﬂuticasone/formoterol
was superior to ﬂuticasone monotherapy for change in
mean FEV1 from pre-dose at baseline to 2 hours post-dose at
week 12 (LS mean between-treatment difference: 0.146 L;
95%CI: 0.042, 0.250; p = 0.006). As described previously,
these data are indicative of the relative contributions of the
ﬂuticasone and formoterol components to the improvements
in lung function observed with ﬂuticasone/formoterol.
Medium-dose ﬂuticasone/formoterol also demonstrated a
signiﬁcantly longer time to discontinuation due to lack of
efﬁcacy (assessed as either an asthma exacerbation or a loss
of asthma control) than placebo (p < 0.001). Furthermore,
fewer patients in the ﬂuticasone/formoterol treatment
group discontinued therapy due to lack of efﬁcacy (10.2%)
than in the ﬂuticasone, formoterol or placebo groups
(12.8%, 20.9% and 39.0%, respectively).42
Analysis of clinically meaningful secondary endpoints also
supported the greater efﬁcacy of ﬂuticasone/formoterol
compared with ﬂuticasone monotherapy. Fewer patients
in the ﬂuticasone/formoterol group had an exacerbation
of any severity (p = 0.030) than in the ﬂuticasone-alone
group. In addition, ﬂuticasone/formoterol was associated
with more rescue-medication-free days (p = 0.042) and
more asthma control days (deﬁned as days with an
asthma symptom score indicating no symptoms; p = 0.027)
than ﬂuticasone alone. Although these endpoints had a
p value of 0.05 versus ﬂuticasone alone, they were
not considered statistically signiﬁcant per the sequential
gatekeeper approach used in the study.42
In both studies described above, ﬂuticasone/formoterol
had a tolerability proﬁle similar to that of its individual
components. Adverse events (AEs) were mostly mild-to-
moderate in severity, with a numerically smaller proportion
of patients in the ﬂuticasone/formoterol group reporting
treatment-emergent AEs compared with those in the
ﬂuticasone, formoterol or placebo groups.42,43
Efﬁcacy of ﬂuticasone/formoterol compared
with its components administered
concurrently via separate inhalers
The efﬁcacy of high-dose ﬂuticasone/formoterol was com-
pared with ﬂuticasone + formoterol administered together
via separate inhalers in a double-blind, double-dummy,
randomized, parallel-group, 8-week study. In this study,
620 adults with persistent, reversible asthma (40% to80%
predicted FEV1 at baseline) were randomly assigned to
8 weeks of treatment with high-dose ﬂuticasone/formoterol
(500/20mg b.i.d.), ﬂuticasone (500mg b.i.d.) plus formo-
terol (24mg b.i.d.), ﬂuticasone alone (500 mg b.i.d.) or low-
dose ﬂuticasone/formoterol (100/10mg b.i.d.; included as
a secondary comparator); all treatments were administered
via an HFA-based pMDI (EudraCT number: 2007-001633-34;
US NCT number: NCT00734318). The primary analysis
population for the non-inferiority comparison (high-dose
ﬂuticasone/formoterol versus ﬂuticasone + formoterol) was
the per-protocol population (PPP; deﬁned as all patients
who completed the study without major protocol violations
affecting the primary endpoint), with conﬁrmatory analyses
performed in the intent-to-treat (ITT) population (all
patients randomized who received at least one dose of
study treatment and had at least one post-dose primary
efﬁcacy [FEV1] measurement). The co-primary endpoints
were mean change in morning pre-dose FEV1 from baseline
to week 8, and mean change in morning FEV1 from pre-
dose at baseline to 2 hours post-dose at the end of week 8;
non-inferiority for the co-primary efﬁcacy endpoints was
concluded if the lower limit of the 95%CI for the between-
treatment difference was −0.2 L.46
The ﬂuticasone/formoterol combination (500/20 mg b.i.d.)
was non-inferior to its components administered concur-
rently (500mg + 24mg, b.i.d.) for both co-primary efﬁ-
cacy endpoints. Fluticasone/formoterol and ﬂuticasone +
formoterol demonstrated similar mean increases in morning
pre-dose FEV1 between baseline and week 8 (LS mean of
the treatment difference: 0.060 L; 95%CI: −0.059, 0.180)
(Fig. 1). For mean change in FEV1 from pre-dose at baseline
to 2 hours post-dose at study end, the increase was similar in
the ﬂuticasone/formoterol (500/20 mg b.i.d.) group and the
ﬂuticasone + formoterol group (LS mean of the treatment
difference: 0.018 L; 95%CI: −0.098, 0.135).46
Fluticasone/formoterol also provided similar improve-
ments to ﬂuticasone + formoterol for several clinically
relevant measures of asthma control, including rescue
medication use, sleep disturbance, asthma symptom and
health status scores, as assessed in the ITT population.
Fluticasone/formoterol had a similar tolerability proﬁle
to ﬂuticasone + formoterol; 19.5% of patients in the
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Figure 1. Fluticasone/formoterol administered as a combination therapy via a single inhaler has an efﬁcacy proﬁle similar to that
of its components administered concurrently (ﬂuticasone + formoterol). Data show (a) the mean change in morning pre-
dose forced expiratory volume in 1 second (FEV1) from baseline to week 8, and (b) change in morning pre-dose FEV1
from baseline to 2 hours post-dose at week 8, for the per-protocol population.46 b.i.d., twice daily. Figures adapted from
Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B, Mansikka H, Efﬁcacy and safety of ﬂuticasone
and formoterol in a single pressurized metered dose inhaler. Respiratory Medicine 2011;105(5):674 82. Copyright 2011,
with permission from Elsevier.
ﬂuticasone/formoterol 500/20mg b.i.d. group reported
an AE, compared with 19.9% in the ﬂuticasone + formoterol
group, 18.7% in the ﬂuticasone/formoterol 100/10 mg b.i.d.
group and 14.2% in the ﬂuticasone alone group. Most AEs
were mild-to-moderate in intensity, with headache, na-
sopharyngitis, viral infection, pharyngitis and asthma being
the most common AEs.46
Efﬁcacy of ﬂuticasone/formoterol versus
ﬂuticasone/salmeterol
A phase 3 clinical trial compared the efﬁcacy and
tolerability of ﬂuticasone/formoterol and ﬂuticasone/
salmeterol.47 In this open-label, active-controlled, random-
ized, parallel-group, multicentre study (EudraCT number:
2006-005926-22; US NCT number: NCT00476073), 202 adults
with asthma (40% and 85% predicted FEV1 at baseline)
were randomly assigned to 12 weeks of treatment with
ﬂuticasone/formoterol (100/10mg or 250/10mg, b.i.d.) or
ﬂuticasone/salmeterol (100/50mg or 250/50mg, b.i.d.),
both administered via HFA-based pMDI with a spacer.
Allocation to treatment dose was stratiﬁed by prior ICS dose;
approximately three quarters of patients were assigned
to the higher study drug dose in each treatment group.
Endpoint analyses were performed for the full analysis set
(FAS; all randomized patients who received study treatment
and had at least one post-dose primary efﬁcacy [FEV1]
measurement) and the PPP (all FAS patients who completed
the study without major protocol violations affecting the
primary efﬁcacy [FEV1] endpoint).47
Fluticasone/formoterol was as effective as ﬂuticasone/
salmeterol for mean pre-dose FEV1 at week 12 (primary
endpoint, with a LS mean of the treatment difference of
−0.061 L; 95%CI: −0.161, 0.040; assessed in the PPP). Non-
inferiority was concluded because the lower limit of the
95%CI was greater than −0.2 L. A key secondary objective
of this study was to assess the time to bronchodilation
(deﬁned as the ﬁrst post-dose measurement at which
FEV1 was at least 12% greater than the pre-dose value).
Fluticasone/formoterol provided signiﬁcantly more rapid
bronchodilation than ﬂuticasone/salmeterol over the 12-
week study period (overall hazard ratio: 1.64; 95%CI:
1.28, 2.10; p < 0.001; FAS).47 The bronchodilatory effects
of study treatments were further explored in a series of
post hoc analyses. On the ﬁrst day of treatment, the
odds of a patient achieving the pre-deﬁned bronchodilation
criterion at 5 minutes post-dose was fourfold greater with
ﬂuticasone/formoterol than with ﬂuticasone/salmeterol
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Figure 2. Fluticasone/formoterol provides more rapid bronchodilation than ﬂuticasone/salmeterol. Values are shown as percentage
change in least-squares (LS) mean forced expiratory volume in 1 second (FEV1) from morning pre-dose at baseline ±
standard error. *p  0.05. Data from a post hoc analysis are shown for the full analysis set. Improvement in lung function
was assessed by change in FEV1 from morning pre-dose at 5, 10, 30, 60, 90 and 120 minutes post-dose, on (a) day 0
and (b) day 84.48 Figure reproduced with kind permission from Springer Science+Business Media B.V. from Figure 2 of
Aalbers R, Brusselle G, Bodzenta-Lukaszyk A, Onset of bronchodilation with ﬂuticasone/formoterol combination versus
ﬂuticasone/salmeterol in an open-label, randomized study. Advances in Therapy 2012;29(11):958 69.
treatment (odds ratio [OR]: 4.0; 95%CI: 2.0, 8.0). Moreover,
the odds of achieving bronchodilation at 5 minutes after
dosing were almost tenfold greater with ﬂuticasone/
formoterol after 12 weeks’ treatment (OR: 9.6; 95%CI:
2.1, 42.9).48 Fluticasone/formoterol also provided greater
increases than ﬂuticasone/salmeterol in LS mean post-dose
FEV1 in the 2 hours following dosing, both on day 0 and
after 12 weeks (overall change on day 0: 17.3% versus 12.6%,
respectively, p = 0.003; day 84: 8.9% versus 6.2%, p = 0.011)
(Fig. 2).48
Fluticasone/formoterol and ﬂuticasone/salmeterol de-
monstrated similar efﬁcacy for other lung function parame-
ters, rescue medication use, asthma symptom scores, sleep
disturbance scores, asthma exacerbations and health status
scores. Fluticasone/formoterol had a similar tolerability
proﬁle to that of ﬂuticasone/salmeterol.47
Efﬁcacy of ﬂuticasone/formoterol versus
budesonide/formoterol
The efﬁcacy and tolerability of ﬂuticasone/formoterol
(250/10mg b.i.d.) compared with budesonide/formoterol
(400/12mg b.i.d.) was assessed in a double-blind, double-
dummy, randomized, two-arm, parallel-group study in 279
adolescent and adult patients with persistent, reversible
asthma (50 80% predicted FEV1 at baseline; EudraCT
number: 2009-017223-25; US NCT number: NCT01099722).
For the primary study endpoint, ﬂuticasone/formoterol and
budesonide/formoterol provided similar changes in mean
morning pre-dose FEV1 from baseline to week 12 (LS mean
treatment difference: −0.044 L; 95%CI: −0.130, 0.043). Non-
inferiority was concluded because the lower limit of the
95%CI for treatment difference was greater than −0.2 L.
Both treatments demonstrated similar efﬁcacy for several
measures of asthma control, including improvements in
asthma symptom scores and sleep disturbance scores and
in number of asthma control days, symptom-free days and
awakening-free nights. The tolerability proﬁles were similar
in both treatment groups.49
Long-term safety and efﬁcacy of ﬂuticasone/
formoterol
The long-term safety and efﬁcacy of ﬂuticasone/formoterol
(100/10 or 250/10mg b.i.d.) was assessed in an open-label,
multicentre study over 6 or 12 months in 472 adult and
adolescent patients with asthma (40 85% predicted FEV1
at baseline; EudraCT number: 2005-003518-14; US NCT
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number: NCT00394121).50 In total, 413 patients (87.5%)
completed the study (of whom 175 participated for
12 months). Overall rates of AEs reported (36.9%) were con-
sistent with those observed in a 1-year study of ﬂuticasone/
salmeterol (250/50mg b.i.d.) and budesonide/formoterol
(adjustable maintenance dosing).51 The majority of AEs
were mild-to-moderate in severity. Asthma exacerbations
were reported by 11.2% of patients (9.7% with mild-to-
moderate exacerbations and 1.9% with severe exacerbations
[deﬁned as requiring additional therapy, hospitalization
or a visit to an emergency department]). Signiﬁcant
improvements from pre-treatment baseline lung function
(FEV1, % predicted FEV1, peak expiratory ﬂow rate and
forced vital capacity) were maintained over the 6- or 12-
month treatment period.50
Drug particle size and lung deposition: the
importance of particle size and ﬁne particle
fraction
Both proximal and distal airways are implicated in the
pathophysiology of asthma; inﬂammation extends from the
large bronchi to the alveoli.52 Therefore, it is necessary for
ICSs to be delivered to both proximal and distal airways;
however, to date no clear clinical beneﬁt of targeting
ICSs to the latter has been demonstrated.53 In contrast,
although b2-receptors are located in all parts of the airways
and are found in greatest density in the alveolar walls,54
the bronchodilatory effects of b2-agonists are due to their
actions on smooth muscle in the proximal airways. Thus,
targeting of b2-agonists to the proximal airways may bemore
important than deposition in distal airways for providing
effective bronchodilation.55 It is therefore logical that
the lung deposition proﬁle of an ICS/LABA combination
product should demonstrate a balance between targeting
bronchoconstriction in the proximal airways and generalized
inﬂammation throughout the lungs, in order to achieve
optimal distribution of deposited drug.
The particle size of inhaled drugs has been identiﬁed as
one of the critical determinants of both the total lung dose
and their regional pulmonary deposition pattern.56 58
However, the extent of lung deposition of polydisperse
aerosols is less dependent on the single particle size
summary statistic (mass median aerodynamic diameter;
MMAD) than it is on particle size distribution around
the MMAD.56,59 The seminal publication by Heyder and
colleagues,57 exploring the relationship between particle
size and regional lung deposition, demonstrated that
particles in the range 2 6mm are associated with both
central and alveolar deposition (Fig. 3).56 58 Therefore,
there is an apparent lower limit of 2mm for an effective
particle size; particles <2mm are prone to deposit largely
in the alveoli and those <1mm are transported to the
alveoli but can also be easily exhaled (and would thus not
exert a therapeutic effect).56,57,60 In light of these data,
it is instructive to note the stage-by-stage particle size
distribution of the ﬂuticasone/formoterol aerosol: in the
eight-stage Andersen Cascade Impactor, operated under
standard pharmacopoeial conditions, the largest individual
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Figure 3. Extent and site of lung deposition of inhaled particles
relative to their size (based on the International Commission
Radiological Protection model).58 Copyrighted material repro-
duced with permission from Mary Ann Liebert, Inc. Publishers,
from Pritchard JN, The inﬂuence of lung deposition on clinical
response. J Aerosol Med 2001;14(Suppl 1):S19 26.
particle size fractions (reaching stages of the apparatus that
correspond to regions of the lungs) of ﬂuticasone/formoterol
are captured in stage 3 (corresponding to particles with
a diameter of 3.3 4.7mm) and stage 4 (corresponding to
particles with a diameter of 2.1 3.3mm).61 These data
support the notion that the particle size characteristics of
the ﬂuticasone/formoterol aerosol are very well suited to
the deposition requirements for an ICS/LABA combination;
however, the clinical impact of such characteristics in real-
world use is yet to be established.
In addition to the distribution of particle sizes, the
ﬁne particle fraction is a key in vitro parameter for
orally inhaled drugs.62 The ﬁne particle fraction is the
percentage of the drug mass that has greatest potential
for penetrating beyond the oropharynx and depositing
throughout the airways.62 In the European Pharmacopoeia,
the ﬁne particle fraction is deﬁned as the proportion
of aerosol drug particles that are <5mm in aerodynamic
diameter.62 The ﬁne particle fraction correlates with
in vivo drug deposition (as measured by scintigraphy and
pharmacokinetic assessment).63,64 A high ﬁne particle frac-
tion reﬂects a desirable balance of high lung deposition and
relatively low oropharyngeal drug deposition. Deposition of
ICS particles in the oropharynx can contribute to systemic
and local adverse effects, including oral candidiasis and
hoarseness/dysphonia, but not to therapeutic beneﬁt.63,65
Given these collective observations, it is encouraging that
the in vitro ﬁne particle fraction of the new ﬂuticasone/
formoterol suspension aerosol is high at ~40% (as assessed
at 28.3 L/min). Importantly, this ﬁne particle fraction is
consistent at ﬂow rates of 28.3 L/min and 60.0 L/min,
in vitro .66
In summary, particle size and ﬁne particle fraction are
the principal in vitro parameters that determine potential
in vivo lung deposition and the risk beneﬁt proﬁle of the
aerosol. The in vitro characteristics of the ﬂuticasone/
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formoterol aerosol are indicative of the potential for
high drug deposition in the lung, an effective regional
lung deposition pattern and a favourable oropharyngeal to
pulmonary deposition ratio. The consistent delivery of a high
ﬁne particle fraction with ﬂuticasone/formoterol may be a
useful characteristic in an inhaled therapy, because patients
often exhibit variability in inhalation ﬂow rate in the day-
to-day use of their inhaler.
Conclusions
Fluticasone/formoterol brings together a rapid-acting LABA
with a potent ICS in a single-aerosol inhaler. A robust
clinical data set demonstrates that ﬂuticasone/formoterol
is superior to either component administered as a mono-
therapy. Fluticasone/formoterol has similar efﬁcacy and tol-
erability proﬁles to ﬂuticasone and formoterol administered
concurrently via separate inhalers. Similarly, ﬂuticasone/
formoterol has similar efﬁcacy and tolerability proﬁles
to budesonide/formoterol and ﬂuticasone/salmeterol and,
importantly, offers the additional beneﬁt of more rapid
bronchodilation than ﬂuticasone/salmeterol.47 The fast
onset of bronchodilation with formoterol, together with
the sustained anti-inﬂammatory effects of ﬂuticasone, are
important treatment characteristics because patients want
a maintenance treatment that they can feel working quickly
and that provides lasting therapeutic beneﬁts.22 26 These
attributes may encourage patients to adhere to their
treatment regimen, a factor that has been associated with
real-world improvements in asthma control.7,67 The emitted
aerosol consistently contains a high ﬁne particle fraction
between ﬂow rates, an attribute that may be valuable given
patient variability in inhalation manoeuvres. In summary,
the ﬂuticasone/formoterol combination aerosol described in
this review represents an additional therapeutic option for
the treatment of asthma in adults who require an ICS/LABA,
with attributes that may be important for effectiveness in
clinical practice.
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